Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
about
Therapy-related myeloid neoplasms - what have we learned so far?Fetal marrow suppression after maternal chemotherapy for leukaemiaTherapy-related myeloid neoplasms: pathobiology and clinical characteristicsRisk of second primary cancers after testicular cancer in East and West Germany: a focus on contralateral testicular cancers.Toxicities of the platinum antineoplastic agents.Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patientsA critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.Late toxicity following curative treatment of testicular cancer.Topoisomerase II inhibitor-related acute myeloid leukaemia.Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemiaTesticular cancer survivorship: research strategies and recommendations.Leukemias related to treatment with DNA topoisomerase II inhibitors.Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapyTherapy related leukemias: susceptibility, prevention and treatment.Therapy-related acute promyelocytic leukemia: a systematic review.DNA topoisomerase II as a target for cancer chemotherapy.Avoiding chemotherapy related late effects in children with curable tumoursTopoisomerase IIα in chromosome instability and personalized cancer therapy.Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution.Cytogenetic abnormalities in childhood acute lymphoblastic leukemia correlates with clinical features and treatment outcome.Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.'VEEP' in children with Hodgkin's disease--a regimen to decrease late sequelae.Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitorAdvances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.Combination of Near Infrared Light-Activated Photodynamic Therapy Mediated by Indocyanine Green with Etoposide to Treat Non-Small-Cell Lung CancerChronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature.Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in ChildhoodThe low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.Secondary malignancies across the age spectrum.Malignant mixed ovarian germ cell tumor with embryonal component.Complications associated with chemotherapy in testicular cancer management.Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.Late Effects of Treatment of Pediatric Central Nervous System Tumors.Optimal management of low-risk gestational trophoblastic neoplasia.Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer ProgressionPrevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine.The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 statusTherapy-related myelodysplasia and acute leukemia.Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.
P2860
Q28071318-55ADB3CC-F713-43A3-8A8C-9AEE0330C7F6Q28367633-FCF87522-F478-46C1-81D5-AB791F2935E7Q28386366-BAD78CEE-4531-4AB9-9A91-E383471A0012Q30317575-AFB561C0-861E-4D52-94AE-F4D947A333C5Q33357351-5B5E1F43-C06C-4CF2-A4A6-9A4AB7F6E7B6Q33665161-CC86FB9E-9AB8-4AFB-AFAA-C053C9698C48Q33735167-900CDA66-C71B-43F1-960B-97F88253493FQ33788925-9B3C860C-6B96-4515-B69A-E1DCCC2D96D5Q33940241-76678388-F114-471A-8C46-7B2FA2096327Q33943185-1E13D17A-8AB3-4A9D-8820-2590586D87CBQ34039684-3B6E34B1-6090-4193-B51B-BFC3E6314188Q34243503-894AE742-A10E-4622-AAA2-B2FBED4953ECQ34248313-272C161A-EAF2-485A-9AA1-D50D44741A18Q34265193-6EABCE33-B6BC-4884-AACB-7F945B394424Q34351253-3222CF64-9859-4368-BAEB-682AC84758F4Q34718447-02F0779B-4A4C-47D2-8568-E41E04763F02Q35448174-5D42ADE8-0638-4E17-A1C5-5890D5C04637Q35498796-E030753A-C29B-474E-A76F-2B1956D334FBQ35544290-684410FD-B3EB-4B03-ADC0-A1295FC6BE0AQ35664675-EEB2FB9D-07B4-403E-9718-30671548B008Q35822033-43D0E237-79AE-40B6-BE1F-F4D9BB4AEE12Q35993073-2B657813-5FFE-4504-8F2A-588B6CC2A475Q36126134-AAC57B7A-0DC9-42A3-A4F9-DBF586CDF500Q36138924-12E3AD0E-A246-4AE8-AEB2-8FC310A6C156Q36394224-6704F428-97C4-4FA6-8B79-76252458D354Q36553802-7CB1D131-4137-48F1-A08F-C385DFD5A2DAQ36911493-AB63BA13-8AED-4679-B025-412B3DEEA60DQ37055896-B5E64A14-DEBE-408D-A756-A5AAE4F6EC5FQ37078647-5AD81515-38F1-4032-8CE7-0D74A417A16AQ37379773-817953B5-9305-42C5-94A7-C433C017FD65Q37418313-CFDB0969-89B5-43EA-AC02-1FA2A23B622FQ37853021-7B7F36B0-0855-4FB8-8CA7-FC4B9E1544F0Q38093037-2A9C1F62-6AE2-4D7F-9060-83E7DDF43D51Q38516808-CD5CFD56-879F-4A15-89D2-16359275BDFEQ38620407-01A89300-74FC-40CD-BE8C-4BF414914B79Q38820055-FC1CB4B3-205F-4BC6-934E-D3E70032780CQ39028505-22DFFCCA-B71E-4C03-B838-5FBD5DA0B853Q39813450-2B7C0712-98D9-4EC6-B583-9A5B1C519680Q40536765-CD96EC0F-1449-4784-BEFB-1EEBAA6DB823Q40594608-4EB3D4CD-B638-48DF-BDE5-5451A32D9384
P2860
Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@ast
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@en
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@nl
type
label
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@ast
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@en
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@nl
prefLabel
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@ast
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@en
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@nl
P2093
P1433
P1476
Increased risk of myelodysplas ...... leomycin for germ-cell tumours
@en
P2093
J Pedersen-Bjergaard
S O Larsen
S W Hansen
P304
P356
10.1016/0140-6736(91)90490-G
P407
P577
1991-08-01T00:00:00Z